Shareholder Class Action

BOSTON - Directors inflated the price of Ariad Pharmaceuticals stock by failing to disclose side effects of its cancer drug Iclusig (ponatinib), and the share price dropped by 66 percent when the truth came out, shareholders claim in Federal Court.